Director, Hartford Headache Center, and professor of neurology, University of Connecticut School of Medicine
The director of the Hartford Healthcare Headache Center in Connecticut and lead investigator on the trial provided some insight into the study's findings.
“It’s an exciting thing to end up thinking about where now there’s an option available with a therapeutic gain, a benefit…are approximately what we end up seeing in triptan studies.”
Recently, Theranica, a biomedical technology developer of electroceuticals for the treatment of migraine and other idiopathic pain disorders, announced positive results for its Nerivio Migra non-invasive neuromodulation device, in the TCH-003 study in the acute treatment of migraine.
The prospective, randomized, double-blind, sham-controlled, and multi-center study assessed the efficacy, safety, and tolerability of the Nerivio Migra on 252 patients who met the International Classification of Headache Disorders, Third Edition (ICHD-3) criteria for migraine with or without aura. They were randomized 1:1 to either the active arm or placebo.
Brian Grosberg, MD, the director of the Hartford Healthcare Headache Center in Connecticut, and lead investigator on the trial, provided some insight into the findings, showing the primary end point of pain relief at 2 hours post-treatment with the device demonstrating a 66.7% response rate in the active arm compared to 38.8% in the placebo arm (P <.0001).
At the American Headache Society’s 2018 Scottsdale Headache Symposium in Arizona, Grosberg sat with NeurologyLive to discuss this device and its potential in the treatment of acute migraine. He noted its comparable outcomes to the pharmacologic acute treatments.